[Risedronate inhibits rat bone marrow adipogenesis and reduces RANKL expression in adipocytes]

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Bone marrow adipogenesis is linked to bone health.
• Osteoporosis involves decreased bone mineral density and altered bone marrow composition.
• Receptor activator of nuclear factor κB ligand (RANKL) plays a role in osteoclastogenesis.

Purpose of the Study:

• To examine risedronate's impact on bone marrow adipogenesis.
• To investigate risedronate's effect on RANKL expression in bone marrow adipocytes.
• To evaluate risedronate's efficacy in an ovariectomized rat model of osteoporosis.

Main Methods:

• Primary rat mesenchymal stem cells (BMSCs) were cultured and treated with risedronate during adipogenic induction.
• Western blotting was used to assess RANKL expression.
• Ovariectomized (OVX) rats were treated with risedronate, followed by bone mineral density (BMD) and bone marrow histopathology analysis.

Main Results:

• Risedronate dose-dependently inhibited BMSC adipogenesis and suppressed RANKL expression.
• In OVX rats, risedronate treatment increased BMD and reduced bone marrow fat content.
• These findings indicate risedronate influences bone marrow microenvironment composition.

Conclusions:

• Risedronate effectively inhibits adipogenic differentiation of BMSCs.
• Risedronate reduces bone marrow fat accumulation and increases BMD in OVX rats.
• Down-regulation of RANKL by risedronate may be a key mechanism in its osteoporosis therapeutic effect.